Dobesilate is an angiogenesis inhibitor

European Journal of Medical Research

Volumn 10, Issue 9, 2005, Pages 369-372

  Cuevas, Pedro ^a   Sanchez I ^b   Lozano, R M ^b   Gimenez Gallego G ^b  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

Author keywords

Angiogenesis; Dobesilate; Fibroblast growth factor; Mouse gelatine sponge assay

Indexed keywords

ACIDIC FIBROBLAST GROWTH FACTOR; ANGIOGENESIS INHIBITOR; DOBESILATE CALCIUM; GELATIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CAPILLARY PROLIFERATION; CONTROLLED STUDY; DIABETIC RETINOPATHY; DRUG MECHANISM; DRUG STRUCTURE; HEMATOLOGIC MALIGNANCY; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; SOLID TUMOR;

ANGIOGENESIS INHIBITORS; ANIMALS; CALCIUM DOBESILATE; FIBROBLAST GROWTH FACTOR 1; GELATIN SPONGE, ABSORBABLE; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC;

EID: 25444467501     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Griffaen AW, Molema G (2000) Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev 52: 237-268
2. Eskens FA (2004) Angiogenesis inhibitors in clinical development: where are we now and where are we going? Br J Cancer 90: 1-7
3. Mousa SA (2000) Mechanisms of angiogenesis: potential therapeutic targets. In: Mousa SA. (ed.) Angiogenesis Inhibitors and Stimulators. Austin: Eurekah.com 1-12
4. Saaristo A, Karpanen T, Alitalo K (2000) Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis. Oncogene 19: 6122-6129
5. Giménez-Gallego G, Cuevas P (1994) Fibroblast growth factors, proteins with a broad spectrum of biological activities. Neurol Res 16: 313-316
6. Ferrara N (1999) Molecular and biological properties of vascular endothelial growth factor. J Mol Med 77: 527-543
7. Ornitz DM, Marie PJ (2002) FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease. Genes Dev 16: 1446-1465
8. Cristofori G (1997) The role of fibroblast growth factor in tumor progression and angiogenesis. Oxford University Press, Oxford, United Kingdom, pp 201-238
9. Cuevas P, Reimers D, Diaz D, Lozano RM, Giménez-Gallego G (1999) Apoptosis of glioma cells induced by the fibroblast growth factor inhibitor 1,3,6-naphthalene-sulfonate. Neurosci Lett 275: 149-151
10. Friesel R, Maciag T (1999) Fibroblast growth factor prototype release and fibroblast growth factor receptor signaling. Thromb Haemostasis 82: 748-754
11. Guzmán-Casado M, Parody-Morreale A, Giménez-Gallego G (2002) Interaction of acidic fibroblast growth factor with heparin, heparan sulfate and polyanions: effects on its activity and structure. In: Cuevas P (ed) Fibroblast growth factor in the cardiovascular system. I. Holzapfel Publishers, Munich, pp 15-44
12. Dickson C, Spencer-Dene B, Dillon C, Fantl V (2000) Tyrosine kinase signaling in breast cancer: fibroblast growth factor and their receptors. Breast Cancer Res 2: 191-196
13. Berthet P, Farine JC, Barras JP (1999) Calcium dobesilate: pharmacological profile related to its use in diabetic retinopathy. Int J Clin Pract 53: 631-636
14. Tejerina T, Ruiz E (1998) Calcium dobesilate: pharmacology and future approaches. Gen Pharmac 31: 357-360
15. Rota I, Chiavaroli C, Garay RP, Hamnaert P (2004) Reduction of retinal albumin leakage by the antioxidant calcium dobesilate in streptozotocin-diabetic rats. Eur J Pharmacol 495: 217-224
16. Lameynardie S, Chiavaroli C, Travo P, Garay RP, Parés-Herbuté N (2005) Inhibition of choroidal angiogenesis by calcium dobesilate in normal Wistar and diabetic GK rats. Eur J Pharmacol 510: 149-156
17. Cuevas P, Arrazola JM (2005) Treatment of basal cell carcinoma with topical dobesilate. J Am Acad Dermatol (in press)
18. Arbiser JL, Byers R, Cohen C, Arbeit J (2000) Altered basic fibroblast growth factor expression in common epidermal neoplasms: examination with in situ hybridization and inmunohistochemistry. J Am Acad Dermatol 42: 973-977
19. Pesenti E, Sola F, Mongelli N, Grandi M, Spreafico F (1992) Suramin prevents neovascularization and tumor growth through blocking of basic fibroblast growth factor activity. Brit J Cancer 66: 367-372
20. Zazo M, Lozano RM, Ortega S, Varela J, Díaz-Orejas R, Ramírez JM, Giménez-Gallego G (1992) High-level synthesis in Escherichia coli of shortened and full-length human aFGF and purification in a form stable in aqueous solution. Gene 113: 231-238
21. Fernández-Tornero C, Lozano RM, Redondo-Horcajo M, Gómez AM, López JC, Quesada E, Uriel C, Valverde S, Cuevas P, Romero A, Giménez-Gallego G.(2003) Leads for development of new naphthalene sulfonate derivatives with enhanced antiangiogenic activity. Cristal structure of acidic fibroblast growth factor in complex with 5-amino-2-naphthalenesulfonate. J Biol Chem 278: 21774-21781
22. Cuevas P, Díaz-González D, Dujovny M (2005) Dihidroxy-2,5 benzenesulfonate (dobesilate) elicits growth arrest and apoptosis in glioma cells. Neurol Res (in press)
23. Auguste P, Gûrsel D, Bikfalvi A (2002) The role of FGF-2 in angiogenesis and neoangiogenesis. In: Cuevas P (ed) Fibroblast Growth Factor in the Cardiovascular System. I. Holzapfel Publishers, Munich, pp 183-205
24. Blanquaert F, Delany AM, Canalis E. (1999) Fibroblast growth factor-2 induces hepatocyte growth factor/scatter factor expression in osteoblasts. Endocrinology 140: 1069-1074
25. Onimaru M, Yonemitsu Y, Tanii M, Nakagawa K, Msaki I, Okano S, Ishisashi H, Shizasuna K, Hasegawa M, Sueshi K. (2002) Fibroblast growth factor-2 gene transfer can stimulate hepatocyte growth expression irrespective of hypoxia-mediated downregulation in ischemic limbs. Circ Res 91: 923-930
26. Nakamura Y, Morishita R, Higaki J, Kida I, Aoki M, Moriguchi A, Yamada K, Hayashi S, Yo Y, Nakano H, Matsumoto K, Nakamura T, Ogihara T. (1996) Hepatocyte growth factor is a novel member of the endothelium-specific growth factors, additive stimulatory effect of hepatocyte growth factor with basic fibroblast growth factor but not with vascular endothelial growth factor. J Hypertension 14: 107-1072
27. Jayson GC, Mulatero C, Ranson M, Zweit J, Jackson A, Broughton L, Wagstaff J, Hakausson L, Groenewegen G, Lawrance J, Tang M, Wank L, Levitt D, Merreaud S, Lehmann FE, Herold M, Zwierzina H (2005) Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancer. Eur J Cancer 4: 555-563
28. Ke LD, Shi Y-X, Im S-A, Chen X, Yung WKA (2000) The relevance of cell proliferation, vascular endothelial growth factor, and basic fibroblast growth factor production to angiogenesis and tumorigenicity in human glioma cell lines. Clin Cancer Res 6: 2562-2572
29. Compagni A, Wilgenbus P, Impagnatiello MA, Cotton M, Christofori G (2000) Fibroblast growth factors are required for efficient tumor angiogenesis. Cancer Res 60: 7163-7169
30. Cuevas P, Carceller F, Díaz-González D, Reimers D, Fernández M, Lozano RM, González-Corrochano R, Giménez-Gallego G (2001) Abolished angiogenicity and tumorigenicity of rat glioma by 1-naphthalenemonosulfonate. Neurosci Lett 308: 185-188
31. Lozano RM, Redondo-Horcajo M, Jiménez MA, Zilberberg L, Cuevas P, Bikfalvi A, Rico M, Giménez-Gallego G (2001) Solution structure and interaction with basic and acidic fibroblast growth factor of a 3-KDa human platelet factor-4 fragment with antiangiogenic activity. J Biol Chem 276: 35723-35734
32. Presta M, Oreste P, Zoppetti G, Belleri M, Tanghetti E, Leali D, Urbinati C, Bugatti A, Rouca R, Nicoli S, Moroni E, Stabile H, Cmaozzi M, Hernández GA, Mitola S, Dell'Eva P, Rusnati M, Ribatti D (2005) Antiangiogenic activity of semisynthetic biotechnological heparins. Low-molecular weight-sulfated Escherichia coli K5 polysaccharide derivates as fibroblast growth factor antagonists. Arterioscler Thromb Vasc Biol 25: 71-76
33. Hurwitz H, Fehrenbacher L, Novotny V, Cartwright T, Hainsworth J, Heim W, Berlin J, baron A, Griffing S, Hohugren E, Ferrara N, Fufe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342